Fri, Sep 19, 2014, 6:36 AM EDT - U.S. Markets open in 2 hrs 54 mins

Recent

% | $
Quotes you view appear here for quick access.

Ironwood Pharmaceuticals, Inc. Message Board

galaberge 104 posts  |  Last Activity: 11 hours ago Member since: Mar 5, 2002
  • galaberge galaberge 11 hours ago Flag

    You don't lose anything to try to have answers. Good initiative. We count on you ugt_92251. Good luck

    Long and strong SYN

    Sentiment: Strong Buy

  • galaberge galaberge 13 hours ago Flag

    1. Maybe some questions about financing the company; what's the plan for the rest of the 2014 year approaching fast.
    2. Are there other news to come for Trimesta this year (What do we expect from Dr. Voskhul in the next months)?
    3. What' the actual status about commercialization of Effirma?

    Sentiment: Strong Buy

  • Reply to

    anyone with medscape ?

    by rc248 14 hours ago
    galaberge galaberge 13 hours ago Flag

    There is no comment to add. It's not pertinent; our SYN-004 is for the C. Diff. infection PREVENTION. There is a big difference between CURING costs and PREVENTION costs.

    I don't know why you ask the question. Maybe you are a short

    Long and strong SYN

    Sentiment: Strong Buy

  • ...This comment sums up the situation.I quote :"You were in the stock while Kanzer was at the helm and he was a freak on drugs who actually took a swing at an FDA official.Now you have the company being run by a CEO who understands how to close deals and get the shareholder maximum value.Riley has already stated that he is in talks with companies and those talks are accelerating.The cognition improvements realized in their phase 2 study and recent presentation on those findings has added more value to our IP and in conjunction with that IP new patents have been submitted.He is a very smart VC guy and he will pull the trigger the the optimum moment.I have owned a lot of pipeline companies and you need to have patience.We have four potential blockbusters if whooping cough goes internationally which is where the largest patient pop exists.You need an iron stomach to ignore the big swings and those big boys who want to scare you away.I am dug in deep and will hold strong as long as Riley is running the show while the smart money of Randal Kirk and Michael Dell continue to support the stock as two of the largest shareholders.Let the traders play with it all they want.The real question is where will we be by the end of 2015.By that time we will have struck a Trimesta Deal and our other three indications will have made major headway.Big pharma will be watching closely as they are all looking to enrich their dried up pipelines.We have the chance to be well north of 10 pps by that timeframe and based on my numbers we should be valued at 1.5B if 3 of our 4 large market indications are successful.If you do the math based on 58mm shares outstanding that comes to 25.86 per share.In my view the range is as wide as 10-25pps due to the uncertainty of FDA approvals.This is not calculating getting the drugs into market.This is a buy out price based on getting all indications through a successful phase 2.At that point I think we are gobbled up by big pharma and our ticker goes away"

    Sentiment: Strong Buy

  • Reply to

    Why You're Wrong About SYN

    by ithurtsalot Sep 15, 2014 10:45 AM
    galaberge galaberge Sep 16, 2014 1:01 AM Flag

    You are not reknowned for your DD . But for blasting a stock and say nonsense you are a champion.

    I invite you to read the following :Synthetic Biologics, Inc. - FORM 8-K - April 21, 2014

    Inside this 8-K you will read and I quote :"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    The Compensation Committee of the Company conducted an evaluation of the compensation of the Company’s CEO and CFO. In order to aid its decision-making, the Compensation Committee considered the compensation practices and the competitive market for executives at companies with which the Company competes for personnel and a study of the Company’s peer group compensation. The competitive market information and peer group study results indicated that the overall compensation of the Company’s CEO and CFO was below market. Based substantially on the Compensation Committee’s review of competitive market information, the Board of Directors of the Company increased the CEO’s base salary to $385,000, granted him an option exercisable for 500,000 shares of the Company’s common stock vesting pro rata on a monthly basis over 36 months and approved a 2013 year-end cash bonus pursuant to the terms of his employment agreement. The Board of Directors of the Company also increased the CFO’s base salary to $335,000, granted him an option exercisable for 150,000 shares of the Company’s common stock vesting pro rata on a monthly basis over 36 months and approved a 2013 year-end cash bonus pursuant to the terms of his employment agreement."

    So both Riley and Ballantyne do not need to buy shares as they have been granted options !!!!!

    Long and strong SYN

    Please do your DD before saying st...d things.

    Sentiment: Strong Buy

  • I quote :

    "Cognitive Dysfunction:

    Trimesta is also being developed for the treatment of cognitive dysfunction in female MS patients.

    This 12-month randomized, double-blind, placebo-controlled Phase II clinical trial is being conducted at four sites in the United States, including UCLA.

    The primary endpoint is the effect on cognitive function as assessed by Paced Auditory Serial Addition Test (PASAT).

    Patient enrollment is ongoing.

    The majority of the costs of this trial are being funded by grants from foundations and charitable organizations and we have pledged approximately $500,000 to UCLA to partially fund this trial payable over three years. An estimated 50-65% of MS patients are expected to develop disabilities due to cognitive dysfunction and there is currently no approved treatment"

    Also go to the address "clinicaltrialsDOTgov/ct2/show/NCT01466114?term=synthetic+biologics&rank=2"

    I was unaware of this.

    Long and strong SYN

    Sentiment: Strong Buy

  • Last days' reaction looks like nothing more than investor disappointment in the company's ability to drive the SYN pipeline without seeing any improvement/partnership in the coming days. In addition, SYN burns money likely leaving it with just enough cash to get through 2014 before it potentially needs to turn to more cash-raising efforts.

    Today's drop could represent a buying opportunity for more risk-willing and biotech-savvy investors. As long as SYN is wise bringing money (without excessive dilution) to achieve its goal with its pipeline all will be OK, I believe the share price could head much higher within few weeks/months from here.

    I have not lost confidence at all. It's just a temporary setback.

    Long and strong SYN

    Sentiment: Strong Buy

  • Reply to

    Trimesta Deal

    by mdr0418 Sep 11, 2014 12:09 PM
    galaberge galaberge Sep 14, 2014 7:25 PM Flag

    My gut feeling is we are very close to a deal. One morning we will have a PR stating SYN is part of a deal. It's impossible with the results we have with Trimesta to do not have a deal. And this deal will be very lucrative for the shareholders. Each day that passes brings us closer to that conclusion.

    All my DD concur to a deal without a doubt : simply too many possibilities.

    Long and strong SYN

    Sentiment: Strong Buy

  • galaberge galaberge Sep 14, 2014 5:40 PM Flag

    ........"BUT NOT IN THE PLACEBO PLUS GLATIRAMER ACETATE GROUP".....

    Sentiment: Strong Buy

  • Reply to

    Small retail knows best with $SYN...

    by ugt_92251 Sep 14, 2014 3:54 PM
    galaberge galaberge Sep 14, 2014 5:36 PM Flag

    Yes. Check my previous posts.....

    Sentiment: Strong Buy

  • galaberge galaberge Sep 14, 2014 5:34 PM Flag

    Did you remove the words DOT ? Also in the address you have to remove the S (not a Secure website)

  • The Abstract presented by the Dr. Voskhul on Friday 12th 2014

    If you are interested in what Dr. Voskhul has presented on Friday 12th 2014 here is the address :(Beware this a website not Secure so remove manually the S)

    Here is :"professionalabstractsDOTcom/msboston2014/planner/indexDOTphp?go=abstract&action=abstract_show&absno=1273&MSBOSTON2014=4d1asi8qa2ctssfv359h9uhfsvokkdv5"

    She had only 12 minutes to do her presentation hence some parts are verbal only....

    I think she was not supposed to present this abstract while writing her paper for a specialised medicine journal.

    Long and strong SYN

    Sentiment: Strong Buy

  • The only TINY criticism came from Mr. Bruce Bebo, The Multiple Sclerosis Society's associate vice president of discovery research who said: "Neurodegeneration is an aspect of MS not addressed by current therapies. Judgment needs to be reserved UNTIL WE SEE THE PAPER PUBLISHED IN A JOURNAL. But I think this is VERY ENCOURAGING."----Period!

    I encourage you to read the answer of Dr. Voskuhl when presenting the latest data at the American Academy of Neurology's recent convention, and saying she will soon submit it for review and publication in a journal. (It may be "The Lancet" in UK or "The New England Journal of Medicine" in USA. She has said that in last June 2014!!!

    Go and google the following: “Female hormone estriol showing promise as MS therapy"- to be sure of the wording.

    So Dr. Voskuhl is now preparing the publication of a paper in a prestigious journal and it may take several months. After the publication NOTHING can go wrong. The FDA approval will follow.

    Long and strong SYN

    Sentiment: Strong Buy

  • Go to the page where Dr. Voskhul is speaking in "common" words. Just go to "articlesDOTphillyDOTcom/2014-06-05/news/50333093_1_estriol-rhonda-voskuhl-ms-therapy"

    This article is so well presented that it should be the PR !

    After read caefully the article published in the "Laboratory Investigation' ( I mentionned this in a previous post ) :"natureDOTcom/labinvest/journal/v92/n8/full/labinvest201276aDOThtml" for further information and clarification of the different terms//words used to understand TRIMESTA is a real success.

    Don't forget to remove the DOT and replace them with real dots !

    We are in the pole position and so Long and Strong SYN.

    Sentiment: Strong Buy

  • galaberge galaberge Sep 13, 2014 11:29 AM Flag

    My answers have been deleted 2 times by Yahoo !!!!!!!!

    Sentiment: Strong Buy

  • His new companies have avoided venture capital.

    So SYN meets his requirements.

    Long and strong SYN

    Sentiment: Strong Buy

  • galaberge galaberge Sep 13, 2014 8:47 AM Flag

    ......that....sorry for the typo error.

    Sentiment: Strong Buy

  • Just read part of my DD........

    "Mr. Riley has more than 23 years of experience in the biotechnology and pharmaceutical industries during which he negotiated numerous worldwide strategic corporate alliances, established joint ventures, and assisted in obtaining venture financings to support product development. Currently, Mr. Riley is Managing Director of Black Crow Ventures, a life science-focused consulting firm with a commercial and transactional focus. He sits on the advisory boards of an Australia-based venture fund (Queensland Biocapital Fund) and Ruga Corporation, a Stanford University spin-out drug discovery company focused on endoplasmic reticulum stress targets.

    Mr. Riley has held senior corporate and commercial development positions with biotech companies Amphora Discovery, Ontogen Corporation, and AvMax. In these positions, he was responsible for raising equity and negotiating alliances including in-licensing, out-licensing, distribution agreements, technology acquisitions and research agreements with large pharmaceutical companies and government agencies. Mr. Riley's pharmaceutical experience includes commercial management and mergers and acquisition roles for PFIZER and SmithKline Beecham. Additionally, Mr. Riley served as CFO and VP Corporate Development for Nichols Institute Diagnostics, a CLIA-certified molecular diagnostics and reference lab, later acquired by Quest Diagnostics. Prior to attending university, Mr. Riley served in the U.S. Army."

    He can help to find a partner for SYN very easily with Randal J. Kirk-the $3 BILLION-man who owns virtually SYN.

    Long and strong SYN

    Sentiment: Strong Buy

  • .........them from damage. None of the other drugs do that.

    I quote the "Laboratory Investigation" :

    "Peripheral and Central Nervous System

    Estriol preserves synaptic transmission in the hippocampus during autoimmune demyelinating disease ! Estriol treatment prevented decreases in excitatory synaptic transmission and lessened the effect of MS (in animals) on PPF (paired-pulse facilitation). In addition, Estriol treatment prevented several neuropathological alterations that occurred in the hippocampus during MS. Cross-modality correlations revealed that deficits in excitatory synaptic transmission were significantly correlated with reductions in trans-synaptic protein binding partners known to modulate excitatory synaptic transmission. To our knowledge, this is the first report describing a functional correlate to hippocampal neuropathology in any MS model. Furthermore, a treatment was identified that prevented both deficits in synaptic function and hippocampal neuropathology...and it's Estriol"

    Long and strong SYN

    Sentiment: Strong Buy

  • Reply to

    REPAIR -- neuroprotective benefits!

    by don_quixote123456 Sep 12, 2014 9:29 AM
    galaberge galaberge Sep 12, 2014 11:40 AM Flag

    By far the best strategy in terms of negotiation and the overall Synthetic business. Results of this morning are more precise than in April and prove SYN was right. Patience. Just watch the coming weeks for other news.

    Long and strong SYN

    Sentiment: Strong Buy

IRWD
12.85+0.33(+2.64%)Sep 18 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.